ApprovalTrail

Approval · Notice of Compliance 19129 · 2017

RAPAFLO: Notice of Compliance 19129

Issued April 5, 2017

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
19129
Date
April 5, 2017
Company
Allergan Pharma Co.Markham, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
New Drug Submission (NDS)
Submission class
Admin
Reason
Manufacturer name change

Products in this notice

BrandDINStatus today
RAPAFLO02361663Cancelled Post Market
RAPAFLO02361671Cancelled Post Market

Medicinal ingredients